The study included 153 patients enrolled at 15 office-based dermatology practices and hospitals in the US. In patients treated with Visonac, a statistically significant reduction in inflammatory acne lesions of 43.8% was achieved compared to 26.6% in the control group (p=0.003). Visonac® also demonstrated improvement in overall acne severity in a significant percentage of patients as compared to control, 44.0% versus 26.4% (p=0.013), respectively. Visonac was well tolerated and no serious adverse events were reported in the study.
Link to congress program and abstract C39, page 52